Pulmonary risk evaluation US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Pulmonary risk evaluation. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Pulmonary risk evaluation US Medical PG Question 1: A 63-year-old man presents to the emergency department because of progressive difficulty with breathing. He has a history of diabetes, hypertension, and chronic bronchitis. He has been receiving medications to moderate his conditions and reports being compliant with his schedule. He reports a recent difficulty with tackling simple chores in the house. He has not been able to walk for more than 1 block over the past few days. His persistent cough has also been worsening with more formation of sputum. During his diagnosis of bronchitis, about a year ago, he had a 40-pack-year smoking history. The patient is in evident distress and uses his accessory muscles to breathe. The vital signs include: temperature 38.6°C (101.5°F), blood pressure 120/85 mm Hg, pulse 100/min, respiratory rate 26/min, and oxygen (O2) saturation 87%. A decrease in breathing sounds with expiratory wheezes is heard on auscultation of the lungs. The arterial blood gas (ABG) analysis shows:
PCO2 60 mm Hg
PO2 45 mm Hg
pH 7.3
HCO3– 25 mEq/L
Which of the following is the most appropriate next step in the treatment?
- A. O2 supplementation (Correct Answer)
- B. Aminophylline
- C. Methylprednisolone
- D. Albuterol
- E. Levofloxacin
Pulmonary risk evaluation Explanation: ***O2 supplementation***
- The patient presents with **severe hypoxemia** (SpO2 87%, PO2 45 mm Hg), which is a life-threatening condition requiring immediate intervention. **Oxygen supplementation** is critical to improve tissue oxygenation and prevent organ damage.
- The patient's presentation is consistent with an acute exacerbation of COPD, likely triggered by infection, where *initial management focuses on correcting hypoxemia* and *relieving bronchospasm*.
- In COPD patients, **controlled oxygen therapy** is essential (target SpO2 88-92%) to avoid worsening CO2 retention, but with SpO2 of 87% and severe hypoxemia, oxygen remains the immediate priority.
*Aminophylline*
- Aminophylline is a **methylxanthine** with bronchodilatory effects, but its **narrow therapeutic index** and significant side effect profile (e.g., arrhythmias, seizures) make it a less favored first-line treatment for acute exacerbations of COPD.
- While it can be considered in severe cases unresponsive to other therapies, it is not the most appropriate immediate next step given the patient's critical hypoxemia, where oxygen is paramount.
*Methylprednisolone*
- **Corticosteroids** like methylprednisolone are important in reducing inflammation during COPD exacerbations and improving lung function.
- However, their full therapeutic effect takes hours to develop, and they do not immediately address the acute, life-threatening hypoxemia present in this patient.
*Albuterol*
- Albuterol is a **short-acting beta-agonist (SABA)**, which is crucial for *bronchodilation* in COPD exacerbations. It should be administered promptly to relieve airway obstruction.
- While essential in managing the exacerbation, addressing the *severe hypoxemia* with oxygen takes immediate precedence to prevent organ damage, as albuterol will not directly increase oxygen saturation to a safe level alone.
*Levofloxacin*
- **Antibiotics** like levofloxacin are indicated when there's evidence of a bacterial infection triggering the COPD exacerbation, as suggested by increased sputum purulence and fever.
- While important for treating the underlying infection, administering antibiotics does not immediately address the *acute respiratory distress* and *severe hypoxemia*, which are the most urgent concerns.
Pulmonary risk evaluation US Medical PG Question 2: A 47-year-old man comes to the physician because of a 7-week history of cough, shortness of breath, and daily copious sputum production. He has had frequent respiratory tract infections over the past several years. Current medications include dextromethorphan and guaifenesin as needed. He does not smoke cigarettes. His temperature is 37.1°C (98.8°F), pulse is 88/min, respirations are 21/min, and blood pressure is 133/84 mm Hg. Pulse oximetry on room air shows an oxygen saturation of 95%. Diffuse crackles and wheezing are heard on auscultation over bilateral lung fields. A CT scan of the chest is shown. The patient is at greatest risk for which of the following complications?
- A. Dysfunction of left ventricle
- B. Infection with Rhizopus species
- C. Neoplastic growth of pleural cells
- D. Damage to bronchial vessels (Correct Answer)
- E. Rupture of pulmonary blebs
Pulmonary risk evaluation Explanation: ***Damage to bronchial vessels***
- The patient's presentation with chronic cough, copious sputum, frequent infections, and diffuse crackles/wheezing, along with the CT scan findings suggestive of **bronchiectasis**, indicates severe and chronic airway inflammation and dilation.
- In **bronchiectasis**, the bronchial arteries undergo **hypertrophy and neovascularization** in response to chronic inflammation, becoming tortuous and fragile.
- These hypertrophied bronchial vessels are at **systemic arterial pressure** (unlike low-pressure pulmonary vessels) and are prone to rupture, leading to **hemoptysis** (can be life-threatening massive hemoptysis in severe cases).
- This is the **most serious acute complication** of bronchiectasis, accounting for 50-90% of massive hemoptysis cases.
*Dysfunction of left ventricle*
- While chronic respiratory illness can lead to **right ventricular dysfunction (cor pulmonale)** due to pulmonary hypertension, it's less directly associated with **left ventricular dysfunction** as a primary complication of bronchiectasis itself.
- The patient's vital signs and oxygen saturation do not immediately indicate acute cardiac compromise.
*Infection with Rhizopus species*
- **Rhizopus** species cause **mucormycosis**, an opportunistic fungal infection primarily seen in immunocompromised individuals (e.g., diabetics, neutropenic patients, those on immunosuppressants).
- There is no information in the vignette to suggest the patient is immunocompromised or has risk factors for mucormycosis.
*Neoplastic growth of pleural cells*
- **Pleural cell neoplasia (mesothelioma)** is typically associated with a history of **asbestos exposure**, which is not mentioned in the patient's history.
- The clinical picture and CT findings are more consistent with chronic inflammatory airway disease than with pleural malignancy.
*Rupture of pulmonary blebs*
- **Pulmonary blebs** are typically associated with **emphysema** or other lung conditions that cause air trapping and are a risk factor for **spontaneous pneumothorax**.
- While the patient has respiratory symptoms, the primary features point towards **bronchiectasis**, and bleb rupture is not the most direct or common complication of this condition.
Pulmonary risk evaluation US Medical PG Question 3: A 70-year-old man presents to a physician with a cough and difficulty breathing during the last 7 years. He has smoked since his teenage years and regularly inhales tiotropium, formoterol, and budesonide and takes oral theophylline. The number of exacerbations has been increasing over the last 6 months. His temperature is 37.2°C (99°F), the heart rate is 92/min, the blood pressure is 134/88 mm Hg and the respiratory rate is 26/min. On chest auscultation breath sounds are diffusely decreased and bilateral rhonchi are present. Pulse oximetry shows his resting oxygen saturation to be 88%. Chest radiogram shows a flattened diaphragm, hyperlucency of the lungs, and a long, narrow heart shadow. The physician explains this condition to the patient and emphasizes the importance of smoking cessation. In addition to this, which of the following is most likely to reduce the risk of mortality from the condition?
- A. Roflumilast
- B. Low-dose oral prednisone
- C. Pulmonary rehabilitation
- D. Supplemental oxygen (Correct Answer)
- E. Prophylactic azithromycin
Pulmonary risk evaluation Explanation: ***Supplemental oxygen***
- The patient's **resting oxygen saturation of 88%** indicates significant hypoxemia, which, if chronic, places a high burden on the cardiovascular system and is a strong predictor of premature mortality in **COPD**.
- **Long-term oxygen therapy (LTOT)** for at least 15 hours a day has been shown to improve survival in patients with severe chronic hypoxemia due to COPD.
*Roflumilast*
- **Roflumilast** is a phosphodiesterase-4 inhibitor that reduces inflammation and is used to decrease exacerbations in severe COPD associated with chronic bronchitis and a history of frequent exacerbations.
- While it can improve lung function and reduce exacerbations, it has not been shown to reduce mortality directly.
*Low-dose oral prednisone*
- **Oral corticosteroids** are primarily used for acute exacerbations of COPD, not for long-term maintenance due to significant systemic side effects like osteoporosis, muscle weakness, and increased infection risk.
- While they can temporarily reduce inflammation, chronic low-dose use is not recommended for mortality benefit and may cause harm in the long run.
*Pulmonary rehabilitation*
- **Pulmonary rehabilitation** is a comprehensive program that improves exercise tolerance, dyspnea, and quality of life in patients with COPD.
- It does not directly reduce mortality but significantly improves functional status and potentially reduces hospitalizations.
*Prophylactic azithromycin*
- **Prophylactic azithromycin** can reduce the frequency of exacerbations in select patients with severe COPD, likely due to its anti-inflammatory and immunomodulatory properties, as well as its bactericidal effect.
- Similar to roflumilast, it reduces exacerbations but has not been shown to reduce mortality directly in COPD patients.
Pulmonary risk evaluation US Medical PG Question 4: A 75-year-old Caucasian man presents to the emergency department with abdominal pain. The patient states he was at home eating dinner when he began to experience severe abdominal pain. The patient has a past medical history of diabetes, hypertension, and atherosclerosis. He lives at home alone, smokes cigarettes, and drinks 1 to 2 alcoholic drinks per day. The patient is given IV morphine and an ultrasound is obtained demonstrating a dilated abdominal aorta. The patient states that his father died of a similar finding and is concerned about his prognosis. Which of the following is the greatest risk factor for this patient's presentation?
- A. Male gender and age
- B. Caucasian race
- C. Cigarette smoking (Correct Answer)
- D. Family history
- E. Atherosclerosis
Pulmonary risk evaluation Explanation: ***Cigarette smoking***
- **Cigarette smoking** is the most significant modifiable risk factor for the development and expansion of **abdominal aortic aneurysms (AAAs)**, directly contributing to vascular inflammation and degradation.
- The patient's history of smoking suggests a strong causal link to his current presentation of a dilated aorta, which is highly indicative of an AAA.
*Male gender and age*
- While **male gender** and **advanced age (over 65)** are significant demographic risk factors for AAA, they are considered non-modifiable and less impactful than smoking in terms of risk magnitude.
- These factors increase predisposition but do not exert the same direct, damaging effect on the arterial wall as chronic smoking.
*Caucasian race*
- **Caucasian race** is a known demographic risk factor for AAA, with higher prevalence rates compared to other ethnic groups.
- However, this is a non-modifiable genetic predisposition and contributes less to the overall risk than modifiable lifestyle factors like smoking.
*Family history*
- A **family history** of AAA, as suggested by the patient's father having a similar condition, increases an individual's susceptibility.
- This is a significant non-modifiable risk factor, indicating genetic predisposition, but its overall impact on aneurysm formation and progression is typically less than that of active smoking.
*Atherosclerosis*
- **Atherosclerosis** is a strong associated condition with AAA, as both share common risk factors and pathology related to arterial wall degeneration.
- While atherosclerosis contributes to the overall vascular compromise, smoking specifically has a more direct and potent effect on promoting aneurysm formation and rupture independently.
Pulmonary risk evaluation US Medical PG Question 5: A 68-year-old man presents with shortness of breath, particularly when walking up stairs and when lying down to go to sleep at night. He also complains of a chronic cough and states that he now uses 2 extra pillows at night. The patient has a history of type 2 diabetes that is well-managed with metformin. He also takes Prozac for a long-standing history of depression. The patient has a 60-pack-year smoking history. He also has a history significant for alcohol abuse, but he quit cold turkey 15 years ago when his brother was killed in a drunk driving accident. Both he and his brother were adopted, and he does not know other members of his biological family. Despite repeated efforts of patient counseling, the patient is not interested in quitting smoking. The physical exam is significant for an obese male using accessory muscles of respiration. The vital signs include: temperature 36.8°C (98.2°F), heart rate 95/min, respiratory rate 16/min, and blood pressure 130/85 mm Hg. The oxygen saturation is 90% on room air. Additional physical exam findings include cyanotic lips, peripheral edema, hepatomegaly, and ascites. The cardiovascular exam is significant for an S3 heart sound and elevated JVP. The pulmonary exam is significant for expiratory wheezing, diffuse rhonchi, and hyperresonance on percussion. The laboratory test results are as follows:
BUN 15 mg/dL
pCO2 60 mm Hg
Bicarbonate (HCO3) 32 mmol/L
Creatinine 0.8 mg/dL
Glucose 95 mg/dL
Serum chloride 103 mmol/L
Serum potassium 3.9 mEq/L
Serum sodium 140 mEq/L
Total calcium 2.3 mmol/L
Hemoglobin 26 g/dL
Bilirubin total 0.9 mg/dL
Bilirubin indirect 0.4 mg/dL
Iron 100
Ferritin 70
TIBC 300
The posterior-anterior chest X-ray is shown in the image. Which of the following interventions is indicated for decreasing the mortality of this patient?
- A. Flu vaccine
- B. Inhaled anticholinergics
- C. ACE inhibitors
- D. Smoking cessation alone
- E. Both smoking cessation and oxygen administration (Correct Answer)
Pulmonary risk evaluation Explanation: **Both smoking cessation and oxygen administration**
- Given the patient's **60-pack-year smoking history**, current respiratory symptoms, and **hypoxemia** (SpO2 90% on room air), **smoking cessation is the single most important intervention to slow the progression of chronic obstructive pulmonary disease (COPD)**.
- **Long-term oxygen therapy (LTOT)** has been shown to **reduce mortality in COPD patients with chronic hypoxemia**. The patient's oxygen saturation of 90% on room air meets the criteria for LTOT.
*Flu vaccine*
- While **influenza vaccination is crucial for preventing exacerbations and reducing morbidity in COPD patients**, it does not directly decrease overall mortality from the underlying disease in the same way as smoking cessation and oxygen therapy.
- It is a recommended prophylactic measure for patients with chronic respiratory conditions, but its impact on all-cause mortality is less direct than the key interventions mentioned.
*Inhaled anticholinergics*
- **Inhaled anticholinergics (e.g., tiotropium)** are bronchodilators that help **improve lung function and reduce symptoms** in COPD, but they do not alter the disease's natural progression or directly reduce mortality.
- They are a cornerstone of **symptomatic management** for COPD but are not considered a mortality-reducing intervention.
*ACE inhibitors*
- **Angiotensin-converting enzyme (ACE) inhibitors** are primarily used in conditions like **hypertension, heart failure, and chronic kidney disease**.
- Although the patient has signs of right-sided heart failure (peripheral edema, hepatomegaly, ascites), which could be secondary to severe COPD (cor pulmonale), ACE inhibitors are **not indicated as a primary treatment for COPD itself** or **to reduce mortality in this context**.
*Smoking cessation alone*
- While **smoking cessation is the most important intervention to slow COPD progression and reduce mortality**, the patient's current **hypoxemia (SpO2 90%) also warrants oxygen administration** for mortality benefit.
- Therefore, **smoking cessation combined with oxygen administration** offers a more comprehensive approach to reducing mortality in this patient.
Pulmonary risk evaluation US Medical PG Question 6: A 60-year-old man presents to the emergency department complaining of worsening exertional dyspnea over the last week. He denies chest pain and lightheadedness but reports persistent cough with white sputum. His past medical history includes hypertension and diabetes mellitus. He has a 50 pack-year history of smoking but denies any illicit drug use or alcohol consumption. His temperature is 101°F (38.3°C), blood pressure is 154/104 mmHg, pulse is 110/min, respirations are 26/min, and oxygen saturation is 88% on a non-rebreather mask. Physical exam is notable for an obese man in distress. The anteroposterior diameter of the patient's chest is increased, and he has decreased breath sounds bilaterally with diffuse expiratory wheezing. Which of the following is the best next step in management?
- A. Muscarinic blocker
- B. Glucocorticoid-analog
- C. Alpha-2 blocker
- D. Beta-2 agonist (Correct Answer)
- E. Alpha-1 blocker
Pulmonary risk evaluation Explanation: ***Beta-2 agonist***
- The patient presents with **acute exacerbation of COPD**, evidenced by his significant smoking history (50 pack-years), barrel chest (increased AP diameter), decreased breath sounds, and diffuse expiratory wheezing.
- **Short-acting beta-2 agonists (SABAs)** like **albuterol** are **first-line bronchodilators** in acute COPD exacerbations, providing rapid relief of bronchospasm by relaxing airway smooth muscle.
- According to **GOLD guidelines**, SABAs are the primary initial bronchodilator, often combined with short-acting muscarinic antagonists (SAMAs) like ipratropium for optimal effect.
- This patient requires **immediate bronchodilation** to address severe dyspnea and hypoxemia (88% on non-rebreather).
*Muscarinic blocker*
- **Short-acting muscarinic antagonists (SAMAs)** like **ipratropium bromide** are important adjunctive bronchodilators in acute COPD exacerbations.
- While SAMAs are effective and typically used **in combination with SABAs**, they are generally considered **adjunctive rather than first-line monotherapy**.
- In clinical practice, both SABAs and SAMAs are often administered together, but when asked for the "best next step," **beta-2 agonist is the more standard initial choice**.
*Glucocorticoid-analog*
- Systemic **glucocorticoids** like **prednisone** are indeed crucial in managing acute COPD exacerbations to reduce airway inflammation and shorten recovery time.
- However, they do **not provide immediate bronchodilation**, which is the most urgent need for this patient with severe respiratory distress and hypoxemia.
- Glucocorticoids are typically administered **after or concurrent with bronchodilators**, not as the initial intervention.
*Alpha-2 blocker*
- **Alpha-2 blockers have no role** in the management of acute respiratory distress or COPD exacerbations.
- These agents are used for conditions like **hypertension** or psychiatric disorders (note: clonidine is actually an alpha-2 **agonist**, not blocker).
- They do not affect airway caliber and are completely unrelated to bronchodilation.
*Alpha-1 blocker*
- **Alpha-1 blockers** like prazosin or doxazosin are used for **hypertension or benign prostatic hyperplasia (BPH)**.
- They have **no role in acute respiratory management** or COPD exacerbations.
- These agents cause peripheral vasodilation and do not affect airway smooth muscle or bronchospasm.
Pulmonary risk evaluation US Medical PG Question 7: A 57-year-old man presents to the clinic for a chronic cough over the past 4 months. The patient reports a productive yellow/green cough that is worse at night. He denies any significant precipitating event prior to his symptoms. He denies fever, chest pain, palpitations, weight changes, or abdominal pain, but endorses some difficulty breathing that waxes and wanes. He denies alcohol usage but endorses a 35 pack-year smoking history. A physical examination demonstrates mild wheezes, bibasilar crackles, and mild clubbing of his fingertips. A pulmonary function test is subsequently ordered, and partial results are shown below:
Tidal volume: 500 mL
Residual volume: 1700 mL
Expiratory reserve volume: 1500 mL
Inspiratory reserve volume: 3000 mL
What is the functional residual capacity of this patient?
- A. 4500 mL
- B. 2000 mL
- C. 2200 mL
- D. 3200 mL (Correct Answer)
- E. 3500 mL
Pulmonary risk evaluation Explanation: ***3200 mL***
- The **functional residual capacity (FRC)** is the volume of air remaining in the lungs after a normal expiration.
- It is calculated as the sum of the **expiratory reserve volume (ERV)** and the **residual volume (RV)**. In this case, 1500 mL (ERV) + 1700 mL (RV) = 3200 mL.
*4500 mL*
- This value represents the sum of the **inspiratory reserve volume (3000 mL)** and the **residual volume (1700 mL)**, which does not correspond to a standard lung volume or capacity.
- It does not logically relate to the definition of functional residual capacity.
*2000 mL*
- This value represents the sum of the **tidal volume (500 mL)** and the **expiratory reserve volume (1500 mL)**, which is incorrect for FRC.
- This would represent the inspiratory capacity minus the inspiratory reserve volume, which is not a standard measurement used in pulmonary function testing.
*2200 mL*
- This value could be obtained by incorrectly adding the **tidal volume (500 mL)** and the **residual volume (1700 mL)**, which is not the correct formula for FRC.
- This calculation represents a miscombination of lung volumes that does not correspond to any standard pulmonary capacity measurement.
*3500 mL*
- This value is the sum of the **tidal volume (500 mL)**, the **expiratory reserve volume (1500 mL)**, and the **residual volume (1700 mL)**.
- This would represent the FRC plus the tidal volume, which is not a standard measurement and does not represent the functional residual capacity.
Pulmonary risk evaluation US Medical PG Question 8: A 45-year-old man with a 15-pack-year smoking history is referred for pulmonary function testing. On physical exam, he appears barrel-chested and mildly overweight, but breathes normally. Which of the following tests will most accurately measure his total lung capacity?
- A. Exhaled nitric oxide
- B. Closed-circuit helium dilution
- C. Spirometry
- D. Body plethysmography (Correct Answer)
- E. Open-circuit nitrogen washout
Pulmonary risk evaluation Explanation: ***Body plethysmography***
- This method accurately measures **total lung capacity (TLC)** by applying **Boyle's Law**, assessing pressure and volume changes within an enclosed chamber.
- It is superior to gas dilution methods for patients with **air trapping** or **poor ventilation distribution**, as it measures all gas in the chest, including trapped air.
*Exhaled nitric oxide*
- This test measures **airway inflammation**, particularly in conditions like asthma, but does not assess lung volumes.
- It is useful for monitoring treatment response and disease severity but does not provide information about **Total Lung Capacity (TLC)**.
*Closed-circuit helium dilution*
- This method estimates **lung volumes** by diluting a known concentration of helium, but it underestimates **TLC** in patients with significant **air trapping** because helium cannot equilibrate with unventilated areas.
- Given the patient's **barrel chest** suggestive of air trapping, this method would be less accurate for measuring his true TLC.
*Spirometry*
- Spirometry measures **forced vital capacity (FVC)** and **forced expiratory volume in one second (FEV1)**, which are dynamic lung volumes reflecting airflow limitation.
- It does not directly measure **Total Lung Capacity (TLC)** or **residual volume**, as it cannot measure the air remaining in the lungs after maximal exhalation.
*Open-circuit nitrogen washout*
- This method estimates **functional residual capacity (FRC)** by washing out nitrogen from the lungs with 100% oxygen, but like helium dilution, it can underestimate volumes in patients with **air trapping**.
- It provides an estimate of the gas that communicates with the airways, excluding any **trapped gas**.
Pulmonary risk evaluation US Medical PG Question 9: A 35-year-old male presents to the emergency room with difficulty breathing. He is accompanied by his wife who reports that they were eating peanuts while lying in bed on their backs when he suddenly started coughing profusely. He has a significant cough and has some trouble breathing. His past medical history is notable for obesity, obstructive sleep apnea, seasonal allergies, and alcohol abuse. He uses a continuous positive airway pressure machine nightly. His medications include cetirizine and fish oil. He has a 10 pack-year smoking history. His temperature is 98.6°F (37°C), blood pressure is 125/30 mmHg, pulse is 110/min, and respirations are 23/min. Which of the following lung segments is most likely affected in this patient?
- A. Posterior segment of right superior lobe
- B. Inferior segment of right inferior lobe
- C. Anterior segment of right superior lobe
- D. Inferior segment of left inferior lobe
- E. Superior segment of right inferior lobe (Correct Answer)
Pulmonary risk evaluation Explanation: ***Superior segment of right inferior lobe***
- The patient was found to be lying on his back while eating peanuts, which is a position that predisposes to aspiration into the **superior segment of the right inferior lobe**.
- Aspiration during supine positioning typically leads to foreign body entry into the most posterior-inferiorly directed airways.
*Posterior segment of right superior lobe*
- Aspiration into the **posterior segment of the right superior lobe** is less common in a supine position unless the patient is positioned slightly to the side.
- While the right lung is generally more prone to aspiration due to the straighter main bronchus, the specific segment depends on body position.
*Inferior segment of right inferior lobe*
- The **inferior segment of the right inferior lobe** would be more likely affected if the patient were in an upright position (e.g., sitting or standing) when aspiration occurred.
- In a supine position, gravity directs aspirated material more towards the superior segment of the inferior lobe.
*Anterior segment of right superior lobe*
- Aspiration into the **anterior segment of the right superior lobe** is rare regardless of body position during aspiration.
- This segment is anatomically less susceptible to gravitational flow of aspirated material compared to more posterior or inferior segments.
*Inferior segment of left inferior lobe*
- The **left main bronchus** branches at a sharper angle than the right, making aspiration into the left lung in general less common than into the right lung.
- If aspiration were to occur in the left lung, the specific segment would still largely depend on the patient's body position.
Pulmonary risk evaluation US Medical PG Question 10: A 63-year-old man presents to the clinic complaining of burning bilateral leg pain which has been increasing gradually over the past several months. It worsens when he walks but improves with rest. His past medical and surgical history are significant for hypertension, hyperlipidemia, diabetes, and a 40-pack-year smoking history. His temperature is 99.0°F (37.2°C), blood pressure is 167/108 mm Hg, pulse is 88/min, respirations are 13/min, and oxygen saturation is 95% on room air. Physical exam of the lower extremities reveals palpable but weak posterior tibial and dorsalis pedis pulses bilaterally. Which of the following is the best initial treatment for this patient's symptoms?
- A. Exercise and smoking cessation (Correct Answer)
- B. Lovenox and atorvastatin
- C. Lisinopril and atorvastatin
- D. Balloon angioplasty with stenting
- E. Femoral-popliteal bypass
Pulmonary risk evaluation Explanation: ***Exercise and smoking cessation***
- This patient presents with symptoms highly suggestive of **peripheral artery disease (PAD)**, characterized by **intermittent claudication** (leg pain worsening with activity and improving with rest), and risk factors like diabetes, hypertension, hyperlipidemia, and smoking.
- **Smoking cessation** is the single most important modifiable risk factor, and a supervised **exercise program** (walking to the point of claudication) is the most effective initial treatment to improve walking distance and quality of life for PAD patients.
*Lovenox and atorvastatin*
- **Atorvastatin** is appropriate for dyslipidemia and cardiovascular risk reduction in PAD patients, but **Lovenox (low molecular weight heparin)** is an anticoagulant typically used for acute thrombotic events or VTE prophylaxis, not initial management of chronic stable claudication.
- While statins are important for secondary prevention, Lovenox does not directly address the primary management of claudication symptoms or underlying atherosclerotic progression in this stable setting.
*Lisinopril and atorvastatin*
- **Lisinopril** is an ACE inhibitor suitable for hypertension, which is important for overall cardiovascular health but not the primary initial treatment for claudication symptoms.
- While both medications address risk factors, they do not directly target the improvement of walking function and symptom relief as effectively as exercise and smoking cessation in the initial phase.
*Balloon angioplasty with stenting*
- Invasive revascularization procedures like **balloon angioplasty with stenting** are typically reserved for patients with more severe symptoms (e.g., rest pain, non-healing ulcers, critical limb ischemia) or those who have failed conservative management like exercise therapy.
- This is not the **best initial treatment** for a patient with stable claudication.
*Femoral-popliteal bypass*
- **Femoral-popliteal bypass** is a surgical revascularization procedure indicated for more severe PAD, particularly in cases of critical limb ischemia or long-segment occlusions that are not amenable to endovascular repair.
- Like angioplasty, it is a more aggressive intervention and not the **initial treatment of choice** for intermittent claudication.
More Pulmonary risk evaluation US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
